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The kidneys are the primary 
organs for maintaining 
homoeostasis of extracellular 
fluid volumes. They receive 
20 - 25% of the cardiac out-
put. The nephron (Fig. 1), which is the 
functional unit of the kidney, determines 
the pharmacokinetics of various drugs. Each 
nephron is capable of producing urine and 
is composed of a glomerulus through which 
fluid is filtered from the blood and a long 
tubular system in which the filtered fluid is 
converted to urine. Surrounding the tubular 
system is an extensive network of capillaries 
– the peritubular capillary network – which is 
supplied with blood from the efferent arteriole, 
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This article on drug nephrotoxicity is detailed, as it is important to be fully aware of renal side-effects of drugs with regard to prevention and 
early diagnosis in order to manage the condition correctly. Many therapeutic agents are nephrotoxic, particularly when the serum half-life is 
prolonged and blood levels are raised because of decreased renal excretion. Distal nephrotoxicity is markedly enhanced when the glomerular 
filtration rate (GFR) is reduced and is a particular threat in elderly patients with so-called ‘normal’ creatinine levels. In patients of 45 - 55 years of age the 
GFR is reduced by about 1 mL/min/year, so that an otherwise healthy person of 80 may have an estimated GFR (eGFR) of <60 mL/min or <50 mL/min, 
i.e. stage 2, 3 or 3b chronic kidney disease (CKD). Furthermore, other effects related to kidney dysfunction may be seen, e.g. worsening of hypertension 
with the use of non-steroidal anti-inflammatory drugs, increased bruising or bleeding tendency with aspirin, and hyponatraemia hypertension 
acidosis with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Digoxin is contraindicated in stage 3 CKD, even in 
a reduced dosage. Other drugs can cause the direct formation of kidney stones, e.g. topiramate (used in the prophylaxis of resistant migraine). 
Levofloxacin (Tavanic) can cause rupture of the Achilles tendon and other tendons. 
Radiocontrast media must be used with care. Occasionally, strategies to prevent acute kidney insufficiency cause irreversible CKD, 
especially in patients with diabetes and those with myeloma who have stage 4 - 5 CKD. Gadolinium in its many forms (even the newer 
products) used as contrast medium for magnetic resonance imaging is best avoided in patients with stages 4 and 5 CKD.
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Table 1. Pathophysiology of drug-induced nephropathy
Level of the nephron Action Drugs
Preglomerular 
(afferent arteriole)
Afferent arteriolar constriction Cyclosporine
Glomerulus Decreased GFR 
(prostaglandins)
Glomerulonephritis 
NSAIDs
Gold, NSAIDs
Penicillamine, cisplatin
Proximal tubules Acute tubular necrosis Aminoglycosides, radiocontrast dyes
Distal tubules Renal tubular acidosis type 4 ACE inhibitors, cyclosporine
Tubules and ducts Crystalluria Acyclovir, sulphonamide
Interstitium Interstitial nephritis Penicillin, allopurinol
Renal papilla Papillary necrosis NSAIDs, analgesics
Table 2. Diuretics: Mechanism of action and indications
Diuretic Mechanism of action Indication
Loop Blocks NaK2Cl (NKCC2) transporter in the thick ascending 
loop of Henle
Blocks NaKCl
Fluid overload
Hypertension 
Hypercalcaemia
Thiazide Distal convoluted tubule
Blocks electroneutral Na/Cl exchanger (NCCT)
Reaches site of action in glomerular filtrate – higher doses required in 
low GFR (ineffective when serum creatinine >200 µmol/L)
Antihypertension, especially in combination with 
ACE inhibitors/ARBs
In combination with loop diuretics for profound 
oedema
Amiloride Blocks ENaC (channel for sodium secretion in collecting ducts under the 
control of aldosterone)
Spironolactone Aldosterone receptor antagonist
Reaches distal collecting tubules via bloodstream (not dependent on GFR)
Often combined with loop diuretics or thiazide to 
capitalise on potassium-sparing action
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blood that has already passed through the 
glomerulus.
The kidneys perform two major functions. 
Firstly, they excrete most of the end-products 
of the bodily metabolism, and, secondly, 
they control the concentration of most 
of the constituents of the body fluids. In 
normal kidney function the counter current 
multiplier system, together with the renin-
angiotensin-aldosterone system (RAAS), 
involves extracellular fluid volume control, 
electrolyte balance, waste product excretion, 
drug and hormone elimination/metabolism, 
blood pressure (BP) and haematocrit 
regulation, and calcium/phosphate balance 
(vitamin D3 metabolism).
Therefore, the kidney is involved in 
absorption, distribution, metabolism, eli-
mination, secretion and filtration, and the 
effects of drugs can be idiosyncratic or accu-
mulative (Table 1).
Many drugs and their metabolites are 
excreted by the kidney by glomerular 
filtration, by tubular secretion, or in some 
cases by both. Renal impairment has a 
significant effect on clearance of these drugs, 
with important clinical consequences.
The glomerular filtration rate (GFR)/
estimated GFR (eGFR) is an important tool 
in staging chronic kidney disease (CKD). 
Pathophysiology 
of drug-induced 
nephropathy
Multiple drugs can affect the same site, 
e.g. acute tubular necrosis, which is the 
commonest cause of renal failure in 
adults, can be caused by aminoglycosides, 
radiocontrast dyes and many other drugs.
A single drug can affect different sites 
in the kidney, e.g. non-steroidal anti-
inflammatory drugs (NSAIDs) can cause 
acute renal failure, interstitial nephritis and 
glomerulonephritis (Table 1).
The nephron and 
electrolyte balance 
The different diuretics include the loop 
diuretics, thiazide diuretics, aldactone and 
osmotic agents. They can by their effect on 
the nephron significantly alter electrolyte 
balance.
The indications for diuretic use include 
heart failure (acute or chronic), pulmonary 
oedema, hypertension, nephritic syndrome, 
hypercalcaemia and hypercalciuria. Diuretic 
drugs increase urine output by the kidney, i.e. 
they promote diuresis. This is accomplished 
by altering the manner in which the kidney 
handles sodium. If the kidney excretes 
more sodium, the water excretion will also 
increase. Most diuretics produce diuresis 
by inhibiting the reabsorption of sodium 
at different segments of the renal tubular 
system. Sometimes a combination of two 
diuretics is given as it can be significantly 
more effective than either compound 
alone, the reason being that one nephron 
segment can compensate for altered sodium 
reabsorption at another nephron segment; 
therefore, blocking multiple nephron sites 
significantly enhances efficacy.
Overall conclusions 
Cumulative event rates from the primary 
outcome (fatal chronic heart disease 
(CHD) or non-fatal myocardial infarction 
(MI)) of the Antihypertensive and Lipid 
Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT)  treatment group, have 
demonstrated that because of the superiority 
of thiazide-type diuretics in preventing 
one or more major forms of cardiovascular 
disease (CVD) and their lower cost, they 
should be the drugs of choice for first-step 
antihypertensive drug therapy.
In Table 2 the mechanism of action and 
indications of diuretics are shown.
Table 3 lists the side-effects and half-life 
of diuretics.
Specific diuretics are listed in Table 4.
Spironolactone
Spironolactone as a class is a potassium-
sparing diuretic. Its mode of action is 
antagonising the effect of aldosterone at 
levels of the mineralocorticoid receptor. 
The aldosterone complex translocates to 
the nucleus to effect gene transcription. 
Indications include the prevention of hypo-
kalaemia in patients on diuretics or digoxin. 
It improves survival in advanced heart failure 
(Randomised Aldactone Evaluation Study).[1]
Spironolactone can be used as an anti-
hypertensive (adjunctive third-line therapy for 
hypertension) or as a first-line drug (patients 
with Conn’s syndrome). Another indication is for 
the treatment of ascites in patients with cirrhosis.
The side-effects of aldactone include anti-
androgenic effects through the antagonism 
of dihydrotestosterone at its binding site.
Drug interactions occur with other 
potassium-sparing drugs, e.g. angiotensin-
converting enzyme (ACE) inhibitors/angio-
tensin II receptor blockers (ARBs) and 
potassium supplements.
(LoSalt may be used as an NaCl substitute 
in cooking.)
Table 5 lists diuretic adverse effects and 
drug interactions.
Table 3. Side-effects and half-life of diuretics
Diuretic Side-effect Half-life
Loop • Electrolyte imbalance 
• Hypokalaemia
• Volume depletion (prerenal uraemia)
• Tinnitus (acts within the cochlea – can synergise 
with  aminoglycoside antibiotics
Oral bioavailability between 
10% and 90%
Acts at luminal side of the 
thick ascending limb (NaK2Cl 
transporter)
Highly protein bound
Rebound after single dose
T½: 4 hours
Thiazide Metabolic 
• Hyperuricaemia, impaired glucose tolerance 
and electrolyte disturbances (hypokalaemia and 
hyponatraemia)
• Volume depletion
T½: 3 - 5 hours
Eliminate waste
Acid base
Electrolytes
Blood volume
Calcium balance
Filter plasma
Reabsorb good stu Adjust Na, K, H
Reabsorb w
ater as needed
Keep m
edulla
hypertonic
Fig. 1. The nephron.
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Nephrotoxic drugs
Nephrotoxic drugs may have a dose-dependent 
effect and/or cause idiosyncratic renal damage. 
Dose-dependent nephrotoxic drugs include 
NSAIDs, such as cyclo-oxygenase-2 (COX-2) 
inhibitors, aminoglycosides and radio-opaque 
contrast materials. Idiosyncratic renal damage 
may be secondary to NSAIDs, penicillins, gold 
and penicillamine. 
NSAIDs
The NSAIDs are commonly used and have a 
wide range of pathological and physiological 
effects. They interfere with prostaglandin 
production, disrupt regulation of renal 
medul lary blood flow and salt water balance. 
With habitual use they can cause chronic renal 
impairment. Their effect can be exacerbated 
by other drugs (antihypertensives, ACE 
inhibitors). They have typical radiological 
features with advanced renal dysfunction.
The pharmacology of the NSAIDs 
includes good absorption and hepatic 
metabolism, they are highly protein bound 
and are excreted by both enterohepatic and 
renal routes. Their half-lives vary. They have 
common therapeutic indications and adverse 
effects. Even though their pharmacokinetics 
and potencies differ and they are from 
different chemical families, their mechanism 
of action is similar. NSAIDs are cyclo-
oxygenase inhibitors with different levels of 
selectivity for COX-1 and COX-2 enzymes. 
Their similarities are more striking than 
their differences. 
The role of prostaglandins is described 
in Table 6.
Table 7 lists the functions of COX-1 and 
COX-2 enzymes.
NSAIDs such as ibuprofen, diclofenac 
and indomethacin have short half-lives, 
with a more rapid effect and clearance. 
The following NSAIDs have a longer half-
life and slower onset and clearance: e.g. 
naprosyn, celecoxib, rofecoxib, nabumetone 
and piroxicam.
NSAID toxicity is wide and variable on 
the gastrointestinal, renal, haematological, 
central nervous and hepatic systems, as well 
as on the skin, and causes allergies. 
Table 4. Specific diuretics
Class Drug Comments
Thiazide Chlorothiazide
Chlorthalidone Thiazide-like in action, not in structure
Hydrochlorothiazide Prototypical drug 
Hydroflumethiazide
Indapamide Thiazide-like in action, not in structure
Methyclothiazide
Metolazone Thiazide-like in action, not in structure
Polythiazide
Loop Bumetanide
Ethacrynic acid  
Furosemide  
Torsemide
K+-sparing Amioloride Distal tubule Na+-channel inhibitor
Eplerenone Aldosterone receptor antagonist; fewer side-effects than 
spironolactone
Spironolactone Aldosterone receptor antagonist; side-effect: 
gynaecomastia
Triamterene Distal tubule Na+-channel inhibitor
Carbonic 
anhydrase 
inhibitors
Acetazolamide Prototypical drug; not used for treating hypertension or 
heart failure
Dichlorphenamide Not used for treating hypertension or heart failure
Methazolamide Not used for treating hypertension or heart failure
Table 5. Adverse effects and drug interactions of diuretics
Class Adverse side-effects Drug interactions
Thiazide Hypokalaemia
Metabolic alkalosis
Dehydration (hypovolaemia), leading to hypotension
Hyponatraemia
Hyperglycaemia in diabetics
Hypercholesterolaemia, hypertriglyceridaemia
Increased low-density lipoproteins
Hyperuricaemia (at low doses)
Azotaemia (in renal disease)
Hypokalaemia potentiates 
digitalis toxicity
NSAIDs: reduce diuretic 
efficacy
Beta-blockers: potentiate 
hyperglycaemia, 
hyperlipidaemias
Corticosteroids: enhance 
hypokalaemia
Loop Hypokalaemia
Metabolic alkalosis
Hypomagnesaemia
Hyperuricaemia
Dehydration (hypovolaemia), leading to 
hypotension
Dose-related hearing loss (ototoxicity)
Hypokalaemia potentiates 
digitalis toxicity
NSAIDs: reduce diuretic 
efficacy
Corticosteroids: enhance 
hypokalaemia
Aminoglycosides: enhance 
ototoxicity, nephrotoxicity
K+-sparing Hyperkalaemia
Metabolic acidosis
Gynaecomastia (aldosterone antagonists)
Gastric problems, including peptic ulcer
ACE inhibitors: potentiate 
hyperkalaemia
NSAIDs: reduce diuretic 
efficacy
Carbonic 
anhydrase 
inhibitors
Hypokalaemia
Metabolic acidosis
Table 6. Role of prostaglandins
Pathological Physiological
• Asthma
• Ulcers
• Diarrhoea 
• Dysmenorrhoea 
• Inflammation 
• Bone erosion 
• Pain
• Fever 
• Temperature control 
•  Bronchial tone 
• Cytoprotection 
• Intestinal mobility 
• Myometrial tone 
• Semen viability 
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The renal effects are secondary to lowered 
renal blood flow, with decreased renal 
prostaglandins. The risk factors are volume 
depletion, and renal, liver and vascular 
disease.
The patient with NSAID toxicity typically 
presents with oedema, high BP and increased 
creatinine levels. The following may also be 
present:  nephrotic syndrome: interstitial neph-
ritis; electrolyte imbalance: K+; attenuation of 
BP medication; papillary necrosis; and kidney 
stones. 
The prostaglandin pathway can be seen 
in Fig. 2.
The classification of NSAIDs is given in 
Table 8.
These drugs have common drug 
interactions with antihypertensive treatment, 
phenytoin, anticoagulants and methotrexate. 
NSAID-induced deterioration of renal 
function depends on the specific drug, the 
dose, the duration of the pharmacological 
effect, and particularly the state of health of 
the recipient.
Renal syndromes associated with the use 
of NSAIDs are:
• vasomotor acute renal failure
• nephrotic syndrome associated with 
interstitial nephritis
• CKD
• sodium retention
• hyponatraemia 
• hyperkalaemia. 
Tissue injury
Phospholipids
Arachidonic acid
Inhibitors
• NSAIDs (non-COX-2)
• Aspirin
Inducers
• Cytokines
• Growth factors
Inhibitors
• COX-2 inhibitors
• NSAIDs (non-COX-2)
• Aspirin
Leukotrienes
• Bronchoconstriction
Cytoprotective prostaglandins
• Protect gastric mucosa
• Aid platelet aggregation
Inammatory prostaglandins
• Recruit inammatory cells
• Sensitise skin pain receptors
• Regulate hypothalamic temperature control
COX-1
(constitutional)
COX-2
(inducible)
Fig. 2. The prostaglandin pathway.
Table 8. NSAID classification
Non-selective inhibition
Acetic acid derivatives
• Diclofenac
• Etodolac
• Indomethacin
• Sulindac
• Tolmetin
Proprionic acid derivatives
• Fenoprofen
• Flurbiprofen
• Ibuprofen
• Ketoprofen
• Naproxen
• Oxaprozin
Fenamate derivatives
• Meclofenamate
• Mefenamic acid
Naphthyl alkanone
• Nabumetone
Salicylates
• Aspirin
• Diflunisal
• Choline magnesium trisalicylate
• Salicylate
Enolic acid derivatives
• Piroxicam
• Meloxicam
Selective COX-2 inhibition
• Celecoxib
• Rofecoxib
Table 7. Functions and location of COX-1 and COX-2 enzymes
COX-1 COX-2
• Constitutively expressed
• Housekeeping function
• Present in every organ
• Stomach, kidney, intestine, platelets
• Vascular endothelium
• Inducible
• Inflammatory 
• Necrotic sites 
• Present in the kidney
• Uterus, ovary, brain, small intestine
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For risk factors for acute vasomotor renal 
failure induced by NSAIDs, see Table 9.
COX-2: Renal
In knock-out mouse models with renal disease 
the pathology shows fibrosis, inflammation and 
papillary changes. Clinical studies have shown 
oedema that resolves with drug withdrawal. 
Drug-induced acute interstitial 
nephritis
The features are renal impairment with tubular 
function defect, such as acidosis, increased 
potassium level, and decreased urinary 
concentration ability. There may be fever, skin 
rash, eosinophilia or eosinophiluria (allergic 
reaction). The kidneys are of normal size (as 
the condition is acute, there is no time for 
the kidneys to shrink), with proteinuria of 
<2 g/day. The condition may occur within 
hours and is reversible in most cases. There is 
interstitial oedema with polymorph infiltration 
and eosinophils. 
The drugs that induce acute interstitial 
nephritis are given in Table 10. 
Diagnosis
• Reversal of renal failure after discontinuing 
the drug.
• Renal biopsy (if the cause of acute renal failure 
is uncertain, or known but a biopsy is taken to 
ascertain that there are no other causes). 
Treatment
• Withdrawal of the drug.
• Corticosteroid (30 - 60 mg/day). 
• Supportive dialysis if needed (temporarily 
in acute renal failure).
Drug-induced chronic interstitial 
nephritis
Features
• Renal impairment that leads to end-stage 
renal disease (ESRD).
• Small-size kidneys, with proteinuria <2 g/day.
• Tubular function defect.
• Occurs within months or year.
• Not reversible, so if left untreated it will 
lead to ESRD. 
• Pathology.
• Tubular atrophy and interstitial fibrosis 
(there is no eosinophilia). 
Possible causes
Analgesics, NSAIDs, cisplatin, cyclosporine.
Aminoglycosides
The aminoglycosides are highly effective 
antimicrobials that are bactericidal, but 
nephrotoxic and ototoxic, with a narrow thera-
peutic range. When prescribing aminogly-
cosides, a once-daily regimen is recommended 
in patients with normal kidneys. There is a 
high peak concentration-enhancing efficacy 
with a long postdose effect. A single daily dose 
is less nephrotoxic. The dose depends on size 
and renal function. It is important to measure 
aminoglycoside levels.
Intravenous contrast
It is commonly used for computed tomo-
graphy scanning, intravenous urography and 
angiography. It is unsafe in patients with pre-
existing renal impairment. The risk increases 
in diabetic nephropathy, heart failure and 
dehydration. Contrast can precipitate ESRF. 
There is a cumulative effect with repeated 
administration. The risk can be reduced by 
using acetylcysteine.[2] 
Prescribing in kidney 
disease
Patients include those:
• with renal impairment 
• on dialysis
• with renal transplants. 
Principles
It is important to establish the type of kidney 
disease. Most patients with kidney failure 
are taking a number of drugs. Therefore, 
interactions are common and care needs 
to be taken to avoid drug toxicity. Patients 
with renal impairment and renal failure are 
often also taking antihypertensive drugs and 
phosphate binders.
Dosing in renal impairment
The loading dose does not usually need to be 
changed. Maintenance doses or the dosing 
interval may have to be adjusted. The half-
life is often prolonged. Therefore, reduce 
the dose or increase the dosing interval. 
Some drugs have active metabolites that are 
excreted renally, e.g. warfarin and diazepam.
Amphotericin
Amphotericin is an antifungal agent for 
topical and systemic use. It is a lipid-soluble 
drug that binds steroid alcohols (ergosterol) 
in the fungal cell membrane, causing 
leakage of cellular content and death. It is 
effective against Candida species and is both 
fungistatic and fungicidal, depending on the 
concentration. It has a broad spectrum of 
activity (Candida, Cryptosporidium).
It is administered intravenously for 
systemic invasive fungal infections and can 
be used orally for gastrointestinal mycosis. 
Side-effects include local/systemic 
effects with infusion (fever). It can cause 
chronic kidney dysfunction, with a decline 
in GFR with prolonged use. Other effects 
include tubular dysfunction (membrane 
permeability), hypokalaemia, renal tubular 
acidosis (bicarbonate wasting type 1/distal), 
diabetes insipidus, and hypomagnesaemia. 
Caution should be taken with prehydration/
saline loading to avoid problems. Toxicity can 
be further reduced substantially by liposomal 
packaging of amphotericin.
Lithium 
Lithium carbonate is used for the treatment 
of bipolar mood disorder. Its toxicity is 
closely related to serum levels. Symptoms 
and signs include cardiovascular arrhythmias 
Table 9. Risk factors for acute vasomotor renal failure induced by NSAIDs
Decreased EABV Normal or increased EABV
• Congestive heart failure
• Cirrhosis
• Nephrotic syndrome
• Sepsis
• Haemorrhage
• Diuretic therapy
• Postoperative patients (with third-space fluid loss)
• Volume depletion/hypotension
• Chronic kidney disease
• Glomerulonephritis
• The elderly
• Contrast-induced nephropathy
• Obstructive uropathy
• Cyclosporine, tacrolimus use 
EABV = effective arterial blood volume. 
Table 10. Drug-induced acute interstitial nephritis 
Classes
Antibiotics Diuretics Others
Penicillins Furosemide Captopril
Cephalosporins Thiazides Amphotericin B
Rifampicin NSAIDs
Sulfonamides
Ciprofloxacin
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(especially junctional dysarrhythmias) and central nervous system 
tremor, confusion, coma and neprhrogenic diabetes insipidus.
Treatment is supportive and includes haemodialysis and 
colonic irrigation for very high levels. There is inadvertent 
toxicity from interactions with ACE inhibitors, and loop and 
thiazide diuretics. Carbamazepine and other anti-epileptics 
increase neurotoxicity. 
Digoxin
Digoxin toxicity (high levels) is demonstrated in 10% of patients and toxicity 
has been reported in 4% of a series of 4 000 digoxin samples assayed. 
The pharmacokinetics include a large volume of distribution 
(reservoir is skeletal muscle). About 30% of stores are excreted in 
urine per day. 
Treatment of digoxin toxicity includes supportive correction 
of electrolyte imbalance. Atropine should be administered 
for bradycardia, and stimulants should be avoided because of 
arrhythmogenicity. Absorption can be limited with the use of 
charcoal (or cholestyramine) within 8 hours. Specific measures 
include the use of digoxin immune fab (Digibind and DigiFab) 
(digoxin-specific antibodies), which binds plasma digoxin, and the 
complex is eliminated by the kidney. These antibodies are used when 
serum drug values approach those of an overdose or are near arrest 
levels. Furthermore, digoxin elimination can be enhanced by using 
charcoal/cholestyramine to interrupt enterohepatic cycling. Dialysis 
is ineffective. 
Antituberculosis drugs
Tuberculosis can be a difficult therapeutic problem in patients with 
renal failure. Rifampicin and isoniazid may be given in the normal 
dosage. Neither is cleared significantly by dialysis. Pyridoxine 
should be given with isoniazid to prevent peripheral neuropathy. 
The plasma half-life of ethambutol is prolonged in renal impairment. 
If the GFR is <30 mL/min, the dose should be 10 - 15 mg/kg/day, 
with a further reduction to 4 mg/kg/day if the GFR is <10 mL/min. 
Although 10 mg/kg/day has been used at these levels of GFR, cases 
of optic atrophy have been reported. Ethambutol is not dialysed to 
any significant extent. Pyrazinamide should be given at a reduced 
dose (10 - 15 mg/kg). Capreomycin is a second-line drug, which 
can be used in isoniazid or streptomycin resistance. It is, however, 
nephrotoxic and ototoxic, but can be administered in a single 
dose of 500 mg. In patients receiving multiple transplants, and 
who are on cyclosporine, rifampicin cannot be used as it reduces 
the concentration of cyclosporine very substantially as a result of 
hepatic enzyme induction. The necessity to use more than three 
agents will be dictated by the nature and severity of the infection. 
Treatment may need to be prolonged (9 - 12 months) in uraemic or 
immunosuppressed patients, in contrast to the shorter courses that 
are preferred in patients with normal renal function. 
Antiretroviral therapy (ART)
Renal toxicity of antiviral therapy is shown in Table 11.
Refer also to the Table on dose adjustments for ART in CKD and 
ESRD in the HIV and CKD section of the article ‘Important causes of 
CKD in South Africa’.[3]
Other drugs
Intravenous iodinated radiocontrast agents labelled with gadolinium 
are used as contrast media in patients undergoing MRI scans. 
Gadolinium is contraindicated in patients with stages 4 and 5 CKD, 
as it can result in a diffuse systemic fibrosis (sclerosis-like syndrome 
with quadriplegia and eventual death). It is perfectly acceptable to 
perform an MRI without contrast if indicated. 
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Table 11. Renal toxicity of antiviral therapy
Antiretroviral class Antiretroviral therapy Renal effect Clinical recommendations
Protease inhibitors Indinavir Nephrolithiasis, crystalluria, dysuria, 
papillary necrosis, acute kidney injury, 
interstitial nephritis
Ritonavir/lopinavir may increase toxicity of 
indinavir
Daily fluid intake of >2 L/day
Ritonavir Reversible acute renal failure (usually in 
combination with nephrotoxic drugs)
Saquinavir, nelfinavir Renal calculi (rare) Increased fluid intake
Reverse transcriptase 
inhibitors
Tenofovir, abacavir Renal tubular damage: proximal tubular 
dysfunction, Fanconi syndrome, 
nephrogenic diabetes insipidus, acute 
tubular necrosis, acute renal failure
Patients on tenofovir should be monitored 
for signs of tubular dysfunction (glycosuria, 
acidosis, mild increase in plasma creatinine 
level, and proteinuria)
Didanosine, lamivudine, 
stavudine
Isolated case reports of tubular dysfunction
Other Cidofovir, adefovir Renal tubular damage, proximal tubular 
dysfunction (cidofovir)
